Berkshire Biomedical Corporation: Company Profile

Background

Mission and Vision

Berkshire Biomedical Corporation is dedicated to enhancing patient wellness by leveraging technology to improve medical outcomes. The company's mission is to provide secure, accurate, and precise personalized medication delivery to the Authenticated Intended User (AIU™) through pioneering the use of biometric technologies combined with cloud-based platforms and a physician-accessible management system.

Primary Area of Focus and Industry Significance

The company specializes in developing innovative drug dispensing technologies aimed at improving medication adherence and patient outcomes. Its lead product, the Computerized Oral Prescription Administration System (COPA™), is designed to deliver controlled and non-controlled liquid oral medications to authenticated users, thereby addressing challenges in medication management and reducing the risks associated with misuse and non-adherence.

Key Strategic Focus

Core Objectives

Berkshire Biomedical's primary objective is to revolutionize medication delivery by integrating biometric authentication and remote monitoring to ensure precise and secure dispensing of medications. This approach aims to enhance patient compliance, improve therapeutic outcomes, and reduce healthcare costs associated with medication errors and non-adherence.

Specific Areas of Specialization

The company focuses on the development of automated, personalized oral liquid dispensing systems that utilize biometric technologies for user authentication. This specialization is particularly relevant in the management of chronic conditions and opioid use disorder, where consistent medication adherence is critical.

Key Technologies Utilized

Biometric Authentication: Employing dual biometric identifiers—fingerprint and dentition recognition—to ensure that medications are dispensed only to the intended user.

Cloud-Based Platforms: Utilizing HIPAA-compliant, encrypted cloud systems for real-time data transmission and storage, facilitating remote monitoring and data analytics.

Automated Dispensing Systems: Developing handheld devices capable of delivering precise doses of liquid medications, integrated with cellular technology for continuous communication with healthcare providers.

Primary Markets Targeted

Berkshire Biomedical primarily targets the healthcare sector, focusing on areas such as chronic pain management and opioid use disorder treatment. The company's technology is designed to be adaptable across various therapeutic areas where medication adherence is a significant concern.

Financials and Funding

Funding History

Berkshire Biomedical has secured multiple funding sources to support its development initiatives:

National Institutes of Health (NIH) Grants: The company has been awarded a total of approximately $2.9 million over two phases of a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH's National Institute on Drug Abuse (NIDA). These funds are designated for the continued development and clinical evaluation of the COPA™ System for at-home methadone administration.

Equity Crowdfunding: In February 2025, Berkshire Biomedical launched an equity crowdfunding campaign on StartEngine, aiming to raise up to $1.5 million to advance its COPA™ technology.

Total Funds Raised

Combining NIH grants and equity crowdfunding, Berkshire Biomedical has raised approximately $4.4 million to date.

Notable Investors

The NIH's NIDA has been a significant investor through its grant funding. Additionally, the equity crowdfunding campaign on StartEngine attracted investments from accredited investors, though specific investor names are not publicly disclosed.

Intended Utilization of Capital

The funds raised are allocated towards:

Product Development: Advancing the engineering and manufacturing of the COPA™ System.

Regulatory Approvals: Supporting the FDA clearance process for the COPA™ System.

Clinical Studies: Conducting research to evaluate the system's effectiveness in real-world settings.

Market Expansion: Establishing partnerships and preparing for commercialization.

Pipeline Development

Key Pipeline Candidates

The primary focus is on the COPA™ System, an automated, personalized oral liquid dispensing device designed to deliver medications securely and accurately to authenticated users.

Stages of Clinical Trials or Product Development

As of February 2026, the COPA™ System is in the pre-commercialization phase, having completed initial development and received FDA acceptance of its 510(k) submission for review. The company anticipates a final clearance decision in the third quarter of 2021.

Target Conditions

The COPA™ System is initially targeting:

Opioid Use Disorder (OUD): Facilitating at-home methadone administration as part of Medication for Opioid Use Disorder (MOUD) treatment.

Chronic Pain Management: Ensuring precise dosing and adherence in the treatment of chronic pain.

Relevant Timelines for Anticipated Milestones

FDA Clearance: Expected in the third quarter of 2021.

Clinical Study Initiation: Following FDA clearance, clinical studies to evaluate patient retention and other benefits are planned.

Technological Platform and Innovation

Proprietary Technologies

COPA™ System: A handheld, automated device that delivers controlled and non-controlled liquid oral medications to authenticated users, integrating biometric authentication and remote monitoring.

Significant Scientific Methods

Biometric Authentication: Utilizing fingerprint and dentition recognition to ensure medication is dispensed to the correct individual.

Cloud-Based Data Management: Employing HIPAA-compliant, encrypted cloud systems for real-time data transmission and storage, enabling remote monitoring and data analytics.

AI-Driven Capabilities

While the current focus is on biometric authentication and cloud-based data management, future developments may incorporate AI-driven analytics to further enhance medication adherence and patient outcomes.

Leadership Team

Key Executive Profiles

Thomas M. Rouse – Board Chair and Co-Founder: With a background in financial technology, Mr. Rouse co-founded Berkshire Biomedical in 2016 and serves as the Chair of the Board of Directors.

Susan Owen – Board Member and Co-Founder: An experienced brand creator and marketing communications executive, Ms. Owen co-founded the company and serves as Vice Chairman.

John Timberlake – President, CEO, and Board Member: Bringing over 30 years of life sciences experience, Mr. Timberlake joined Berkshire Biomedical in April 2021, leading the company's strategic direction and operations.

Christy Corey – Head of Operations: With 25 years of experience in product and project strategy, Ms. Corey has been with Berkshire Biomedical since 2016, overseeing operations and product development.

John Kirkpatrick – Head of Information Technology: Joining in 2018, Mr. Kirkpatrick brings over 35 years of IT experience, managing the company's technology infrastructure and data systems.

Leadership Changes

As of February 2026, there have been no significant recent changes or appointments within the company's leadership.

Competitor Profile

Market Insights and Dynamics

The market for medication adherence solutions is expanding, driven by the increasing prevalence of chronic diseases and the need for effective management of opioid use disorder. Technological advancements in telemedicine and remote monitoring are creating opportunities for innovative solutions like the COPA™ System.

Competitor Analysis

Key competitors include companies developing digital health solutions for medication management and adherence. While specific competitors are not detailed in the available information, Berkshire Biomedical differentiates itself through its unique combination of biometric authentication and automated medication dispensing.

Strategic Collaborations and Partnerships

Berkshire Biomedical has engaged in strategic collaborations to advance its technology, including partnerships with world-class engineers, FDA regulatory advisors, and patent attorneys. Additionally, the company has received significant support from the NIH's NIDA through grant funding, underscoring the potential impact of its technology in addressing public health challenges.

Operational Insights

Berkshire Biomedical's focus on biometric authentication and automated dispensing positions it uniquely in the market, offering a secure and precise solution to medication management challenges. The company's strategic collaborations and funding support enhance its capacity for innovation and market penetration.

Strategic Opportunities and Future Directions

The company plans to expand the COPA™ System's application beyond opioid use disorder and chronic pain management to other therapeutic areas where medication adherence is critical. Future developments may include integrating AI-driven analytics to further enhance patient outcomes and exploring additional strategic partnerships to accelerate commercialization.